CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 68 enrolled
Drug / intervention
GDC-0449drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00607724
NCT00607724Phase 1Completed
CompareCT.gov

An Open-Label, Phase I Study of Systemic Hedgehog Pathway Antagonist, GDC-0449, in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or For Whom No Standard Therapy Exists

Genentech, Inc.·interventional·Posted Feb 6, 2008·Updated Oct 8, 2015

In Brief

A Phase 1 clinical trial evaluating GDC-0449 for Unspecified Adult Solid Tumor, Protocol Specific. Completed, enrolled 68 participants.

Detailed Summary

RATIONALE: Drugs used in chemotherapy, such as GDC-0449, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I trial is studying the side effects and best dose of GDC-0449 in treating patients with locally advanced or metastatic solid tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUnspecified Adult Solid Tumor, Protocol Specific
Countries--
CollaboratorsNational Cancer Institute (NCI), Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Timeline

Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 6, 2008
Enrollment StartApr 1, 2007
Primary CompletionNov 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 18.4 years ago

Interventions

GDC-0449drug